New App-Based study tracks Real-Life impact of melanoma combo therapy

NCT ID NCT07022457

First seen Apr 15, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study follows 50 adults in the UK with advanced melanoma who are starting a two-drug treatment (encorafenib and binimetinib). Instead of testing if the drugs work, researchers want to see how the treatment affects patients' daily lives and well-being over two years. Participants use a smartphone app to answer surveys about their quality of life, while doctors also provide medical records.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA, BRAF V600 MUTATION POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB20QQ, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, B152GW, United Kingdom

  • Royal Marsden Hospital

    London, SW36JJ, United Kingdom

  • Royal Preston Hospital

    Preston, PR26GP, United Kingdom

  • Southampton General Hospital

    Southampton, SO166YD, United Kingdom

  • Southend University Hospital

    Westcliff-on-Sea, Essex, SS00RY, United Kingdom

  • University Hospital Coventry and Warwickshire

    Coventry, CV22DX, United Kingdom

Conditions

Explore the condition pages connected to this study.